Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aclaris Therapeutics, Inc. (ACRS) vs Allogene Therapeutics, Inc. (ALLO)

Aclaris Therapeutics, Inc. and Allogene Therapeutics, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Allogene Therapeutics, Inc. are of similar size ($594.2M and $589.0M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against −51.0%. Aclaris Therapeutics, Inc. has the higher net margin (−921.5% vs −3,517.4%) and the lower return on invested capital (−163.4% vs −108.8%). Across the 16 metrics below, Aclaris Therapeutics, Inc. leads on 8 and Allogene Therapeutics, Inc. on 8.

Valuation

Metric ACRS ALLO Biotechnology median
P/E n/m n/m 7.88
P/S 89.44 115.35 11.47
P/B 5.90 1.24 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 78.52 44.66 10.73
Earnings yield (11.26%) (40.61%) (28.84%)
Free cash flow yield (8.46%) (18.90%) (23.03%)

Profitability

Metric ACRS ALLO Biotechnology median
Gross margin 12.90% 100.00% 65.16%
Operating margin (1,050.16%) (3,832.45%) 0.00%
Net margin (921.50%) (3,517.41%) 0.00%
Free cash flow margin (756.50%) (2,180.62%) 0.00%
Return on equity (59.10%) (42.39%) (57.72%)
Return on assets (41.07%) (32.43%) (49.22%)
Return on invested capital (163.35%) (108.81%) 0.00%

Growth

Metric ACRS ALLO Biotechnology median
Revenue growth (TTM) (51.04%) 7,613.11% 5.64%
EPS growth (last fiscal year) 69.01% 34.09% —
Revenue growth, 5-year CAGR 3.84% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS ALLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 10.72 4.73
Net debt to EBITDA 1.20 1.24 0.96

Dividend

Metric ACRS ALLO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ACRS ALLO Biotechnology median
Market cap 588.97m 594.24m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack